Skip to main content
. 2020 Apr 27;10:7025. doi: 10.1038/s41598-020-63975-9

Table 3.

(a) Dosimetric homogeneity indices in the PTV calculated for treatment plans 1 to 4 (all fields). The volume (%) that receives more than 110% and less than 93% of the prescribed dose (D50), V93 and V110 respectively, are also given. (b) PVDR and s-index in the PTV evaluated for treatment plans 3 and 4 (individual fields). The PVDR uncertainties are the standard deviation of the PVDR, as defined in section II.3.

Plan No. Glioma Meningioma
PVDR (PTV) s-index (%) D95 (%) V93 (%) V110 (%) PVDR (PTV) s-index (%) D95 (%) V93 (%) V110 (%)
(a)
1 1.05 ± 0.06 2.2 98 0 0 1.06 ± 0.08 3.7 94 1.0 0
2 1.03 ± 0.04 3.3 97 0 0 1.04 ± 0.08 5.4 91 7.6 0.3
3 1.04 ± 0.08 5.5 93 2.0 0.2 1.05 ± 0.12 7.0 91 12.2 3.4
4 1.13 ± 0.16 11.2 88 14.5 7.8 1.05 ± 0.14 9.4 88 20.2 15.7
Plan 3 Plan 4
Glioma Meningioma Glioma Meningioma
PVDR (PTV) s-index (%) PVDR (PTV) s-index (%) PVDR (PTV) s-index (%) PVDR (PTV) s-index (%)
(b)
Field 1 1.06 ± 0.12 8.2 1.04 ± 0.12 8.7 1.2 ± 0.3 16.5 1.09 ± 0.23 15.3
Field 2 1.10 ± 0.14 9.8 1.06 ± 0.14 8.2 1.3 ± 0.4 23.3 1.06 ± 0.16 11.0
Field 3 1.06 ± 0.10 6.7 1.2 ± 0.2 15.7